2. Search Result
Search Result
Results for "

kidney toxicity

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W016034
    Acetaminophen glucuronide sodium salt

    p-Acetamidophenyl β-D-glucuronide sodium salt; p-AAPG sodium salt

    		 Others Infection
    Acetaminophen glucuronide is a safe and effective antipyretic analgesic. Acetaminophen glucuronide is potentially toxic to liver and kidney .
    Acetaminophen glucuronide sodium salt
  • HY-B0303A
    Diphenhydramine hydrochloride
    3 Publications Verification

    		 Histamine Receptor Endogenous Metabolite Bacterial Apoptosis Inflammation/Immunology Endocrinology Cancer
    Diphenhydramine hydrochloride is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB) .
    Diphenhydramine hydrochloride
  • HY-N12007
    OAT1/3-IN-1

    		Others Metabolic Disease
    OAT1/3-IN-1 (compound 7) is a dual inhibitor of OAT1 and OAT3. OAT1/3-IN-1 can reverse the toxicity of Cys-Hg on HEK-OAT1 cells (10 μM) and has a potential protective effect on the kidneys. OAT1/3-IN-1 can be used to study mercury-induced kidney damage .
    OAT1/3-IN-1
  • HY-N12008
    OAT1/3-IN-2

    		Others Metabolic Disease
    OAT1/3-IN-2 (compound 8) is a dual inhibitor of OAT1 and OAT3. OAT1/3-IN-2 can reverse the toxicity of Cys-Hg on HEK-OAT1 cells (10 μM) and has a potential protective effect on the kidneys. OAT1/3-IN-2 can be used to study mercury-induced kidney damage .
    OAT1/3-IN-2
  • HY-Y1840
    3-Methoxyphenol

    		Others Neurological Disease
    3-Methoxyphenol is a phenolic compound that is biologically toxic. 3-Methoxyphenol is systemically absorbed, disrupts the function of the liver, kidneys, central nervous system, and redox processes, and increases levels of Hb, red blood cells, and white blood cells in the body.
    3-Methoxyphenol
  • HY-111054A
    N-methyl-N-dithiocarboxyglucamine sodium

    MDCG sodium

    		 Endogenous Metabolite Others
    N-methyl-N-dithiocarboxyglucamine (MDCG) sodium mobilizes and promotes excretion of metallothionein-bound 109Cd in mouse model. N-methyl-N-dithiocarboxyglucamine significantly lowers the Cd content of both the liver and kidney, which is organs most susceptible to Cd-induced toxicity .
    N-methyl-N-dithiocarboxyglucamine sodium
  • HY-N125722
    Venturicidin A

    Aabomycin A1

    		 ATP Synthase Antibiotic Infection
    Venturicidin A (Aabomycin A1), from actinomycetes, is a membrane-active natural product inhibitor of ATP synthase. Venturicidin A potentiates the aminoglycoside antibiotic gentamicin against multidrug-resistant clinical isolates of Staphylococcus, Enterococcus, and Pseudomonas aeruginosa. Venturicidin A shows noticeable toxicity toward human embryonic-kidney (HEK)cells with an IC50 of 31 μg/mL.
    Venturicidin A
  • HY-125923
    Djenkolic acid

    		Others Metabolic Disease
    Djenkolic acid is a sulfur-containing non-protein amino acid naturally found in the djenkol beans of the Southeast Asian plant Archidendron jiringa. Djenkolic Acid often causes renal injury, including hypersensitivity to or a direct toxic effect of a djenkol bean metabolite, resulting in acute kidney injury and/or urinary tract obstruction by djenkolic acid crystals, sludge, and/or possible ureteral spasms .
    Djenkolic acid
  • HY-144332
    PHD2/HDACs-IN-1

    		HDAC HIF/HIF Prolyl-Hydroxylase Cancer
    PHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC50s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) .
    PHD2/HDACs-IN-1
  • HY-132613
    Lumasiran sodium

    		Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-132588
    Lumasiran

    ALN-G01

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .
    Lumasiran

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: